U.S. market Closed. Opens in 2 hours 50 minutes

SUPN | Supernus Pharmaceuticals, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for SUPN we got that it has average fundamentals where Valuation is considered to be slightly undervalued, Profitability is unacceptably poor, Growth is bad and Health is strong.

Valuation (64%)

Company Industry
P/E Ratio (TTM) 356.07 17.23
PEG Ratio (TTM) 2.67 -32.93
P/S Ratio (TTM) 2.97 5.23
P/B Ratio (TTM) 1.95 4.53
P/FCF Ratio (TTM) 12.11 14.91
Price to 5YR AVG Earnings Ratio 25.20 24.57
Price to 5YR AVG FCF Ratio 14.90 18.08

Profitability (30%)

Company Industry
ROA (TTM) 0.40% 4.02%
ROE (TTM) 0.56% 27.89%
Net Profit Margin (TTM) 0.83% -9.55%
ROIC 5YR AVG 10.21% 12.32%

Growth (43%)

4QTR AVG 3YR AVG 5YR AVG
EPS 3,440.60% -13.72% -25.43%
Revenue 6.22% 13.32% 9.22%
Net Income 3,539.17% -14.59% -25.59%
Cash Flow 73.40% -0.16% -2.70%

Health (70%)

Company Industry
Current Ratio (TTM) 1.91 2.51
Quick Ratio (TTM) 1.69 1.87
D/E Ratio (TTM) 0.04 -0.07
Interest Coverage (TTM) -8.51 16.86
Piotroski F-Score 7 6
Altman Z-Score 4.48 4.41
LTL to 5YR AVG FCF 0.26 3.86
Shares Outstanding Growth 5YR AVG 0.18% 24.93%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙